Insurers pay docs to stick to regimens

Share this article:

Insurance companies are getting more closely involved with cancer treatment options. The Wall Street Journal reports that the strategies include WellPoint's latest rollout—a $350 per-month, per-patient incentive for doctors who adhere to the insurer's recommended regimens—as well as insurer Highmark, which eliminated the pay reimbursement differential between hospital and in-office settings. Highmark's chief medical officer said they found they were being charged hospital rates even when a medication was given at an office, saying “they simply relabeled the room” to get the higher reimbursement rate.

WellPoint estimates that the program will end up saving the insurer around $5.4 billion. The company told the WSJ that its policy will not clash with genetics-based protocols and that it will not punish doctors for using treatments that are not on its recommended list.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Imbruvica lassoes CLL indication

The FDA slapped a Breakthrough Therapy label on the CLL indication pursuit in February.

FDA asks social media "how'm I doin?"

The FDA's Center for Drug Evaluation and Research's Office of Communications wants a system that will help assess its messaging reach across the interwebs and its many forums.

Reckitt Benckiser wants out of pharma

The company plans to spin off its pharmaceutical unit.